Topsalycin in the treatment of prostate cancer: an update

Some 3 years ago we first commented on a Phase II trial of a drug now called topsalycin (but then known as PRX302) in the treatment of low- to intermediate-risk, localized prostate cancer.

Three trials of topsalycin now appear to have been completed in the treatment of prostate cancer, and the results appear to be open to differing interpretations.

The data from the most recent trial were reported in a media release issued yesterday (December 17) by the developing company (Sophiris Bio).

In that trial, the company had experimented to see whether giving patients a second, transperitoneal, intraprostatic injection of topsalycin had greater efficacy than just a single injection. There appears to have been no indication that this was the case.

This, what we know from the completed studies is the following:

A single administration of topsalycin and associated follow-up biopsy data at 6 months post-treatment show that:

  • 15/37 patients (41 percent) exhibited a partial response to treatment, defined as a reduction in maximum cancer core length (MCCL) and/or Gleason pattern, but the targeted lesion was still deemed clinically significant.
  • 12/37 patients (32 percent) did not respond to treatment, defined as no change in the targeted lesion or an increase in MCCL and/or Gleason pattern.

Despite the fact that these data are at best “equivocal”, it appears that Sophiris Bio is willing to press forward with a Phase III clinical trial of topsalycin in the treatment of low- and intermediate-risk prostate cancer, although no details about this trial are available to date, and they will likely have to be based on discussions with regulatory authorities in Europe and in the US.

Since we have no way to know whether a change in Gleason score or any reduction in MCCL on a post-treatment biopsy compared to a diagnostic or standardized pre-treatment biopsy is clinically meaningful, it is a little unclear to your sitemaster what Sophiris is hoping to be able to use as an endpoint in a randomized, Phase III clinical trial.

The idea of being able to give one or more injections of a drug directly into the prostate as a method to treat localized prostate cancer is obviously very attractive. Proving the clinical efficacy of such a treatment may be a good deal more difficult, however.


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: